Enhancing Chemotherapy Efficacy: Investigating the Synergistic Impact of Paclitaxel and cd73 Gene Suppression on Breast Cancer Cell Proliferation and Migration.

Autor:	Hamidnia F; Molecular Biology and Genetics, Biruni University, Istanbul, TUR., Aslan ES; Molecular Biology and Genetics, Biruni University, Istanbul, TUR., Najafi S; Medical Sciences, Immunology Research Center, Tabriz University, Tabriz, IRN., Baghbani E; Medical Sciences, Immunology Research Center, Tabriz University, Tabriz, IRN., Eslamkhah S; Molecular Biology and Genetics, Biruni University, Istanbul, TUR., Baradaran B; Medical Sciences, Immunology Research Center, Tabriz University, Tabriz, IRN.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Jul 21; Vol. 16 (7), pp. e65027. Date of Electronic Publication: 2024 Jul 21 (Print Publication: 2024).
DOI:	10.7759/cureus.65027
Abstrakt:	Background Enhancing chemotherapy efficacy is crucial in breast cancer treatment. This study examines the synergistic effects of paclitaxel, a common chemotherapeutic drug, and Cluster of differentiation 73 ( cd73) gene suppression via siRNA on MDA-MB-231 breast cancer cells. Methods MDA-MB-231 cells were transfected with CD73 siRNA and treated with paclitaxel. Cell viability, apoptosis, and migration were assessed by using MTT assays, Annexin V-FITC/PI staining, and wound healing assays, respectively, with flow cytometry analyzing cell cycle distribution. Results The combination of CD73 siRNA and paclitaxel significantly reduced cell viability, lowering paclitaxel's IC50 from 14.73 μg/mL to 8.471 μg/mL, indicating enhanced drug sensitivity. Apoptosis rates increased with the combination treatment, while cell migration was significantly inhibited. Flow cytometry revealed cell cycle arrest in the Sub-G1 and G2-M phases. Conclusion These findings suggest that cd73 gene suppression enhances paclitaxel's cytotoxic effects, promoting apoptosis and inhibiting cell migration in MDA-MB-231 breast cancer cell line. This combined strategy shows promise for improving breast cancer treatment outcomes by increasing the efficacy of existing chemotherapeutic regimens, warranting further research to explore its potential clinical applications and effectiveness in other breast cancer cell lines and models. Competing Interests: Human subjects: All authors have confirmed that this study did not involve human participants or tissue. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Hamidnia et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu